HLA-A*11: 01 restrictive neoantigen peptide based on malignant pleural effusion tumor cells and application of HLA-A*11: 01 restrictive neoantigen peptide

By isolating and screening HLA-A*11:01-restricted neoantigen peptides from malignant pleural effusions of patients with advanced lung cancer, the problem of inability to obtain neoantigens was solved, and the stimulation of tumor-specific T cells and the provision of immunotherapy targets were achieved.

CN120774992AActive Publication Date: 2025-10-14PEOPLES HOSPITAL PEKING UNIV
5 Cites 0 Cited by

Patent Information

Application Number
CN202510844940.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-23
Publication Date
2025-10-14
Estimated Expiration
2045-06-23

AI Technical Summary

Technical Problem

Existing technologies make it difficult to effectively obtain tumor neoantigens from patients with advanced lung cancer who are inoperable, which affects the implementation of immunotherapy.

Method used

By isolating tumor cells from malignant pleural effusion, high-throughput sequencing and computer algorithms were used to predict candidate neoantigens. Their affinity with HLA molecules was verified by Tetramer staining experiments. HLA-A*11:01-restricted neoantigen peptides were screened and specific T cell responses were stimulated.

Benefits of technology

We have obtained neoantigen peptides with high affinity to HLA molecules, which can stimulate tumor-specific T cell responses, provide targets for tumor immunotherapy, solve the problem of inability to obtain neoantigens, and provide a new treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of tumor immunotherapy, in particular to an HLA-A * 11: 01 restrictive neoantigen peptide based on malignant pleural effusion tumor cells and application of the HLA-A * 11: 01 restrictive neoantigen peptide. The tumor neoantigen polypeptide is separated and screened from malignant pleural effusion of a lung cancer patient, and the amino acid sequence of the neoantigen polypeptide is shown as any one of SEQ ID NO.1-9. The tumor neoantigen polypeptide has high affinity with HLA molecules, can stimulate generation of tumor specific T cells, and can be used as a target spot for clinical treatment or diagnosis of tumors. The invention also provides a method for separating and screening the tumor neoantigen polypeptide, the method solves the problem that the neoantigen of a non-surgical treatment patient cannot be obtained, and an effective method is provided for the development of the tumor neoantigen polypeptide.
Need to check novelty before this filing date? Find Prior Art